When the market tells you nothing: navigating salary opacity in US Life Sciences

The number is stark. Across more than 10,000 active US Life Sciences postings in our corpus over the trailing quarter, 0% of postings disclose a salary range. Not a rounding artifact, not a modest shortfall — zero. Whatever effect pay transparency conversations have had on other sectors, they have not moved the needle on disclosed compensation in this market, at this level.

That absence is itself a data point, and it changes how a careful job search should be structured.

What zero disclosure actually means

It does not mean compensation is arbitrary or unknowable. It means the information is withheld from the posting — deliberately, systematically, and nearly universally. Employers retain full negotiating information while candidates arrive without a floor, a ceiling, or a midpoint. The asymmetry is complete.

The practical consequence is that a job description, on its own, cannot tell you whether a role is worth pursuing financially. Title, scope, seniority signals, and employer reputation become proxies — imperfect ones. A Director title at a mid-stage biotech and a Director title at a large pharma can sit materially apart in total cash, without any signal of that gap appearing in the posting itself. Treating postings as equivalent because they share a title is a category error the market quietly encourages.

For experienced professionals who are already employed and evaluating whether a move is worth the disruption, this opacity has a real cost. Every exploratory conversation, every screening call taken without compensation context, represents time spent navigating a process that could resolve at a number well below what a move would require. The market does not compensate you for that time.

A posting tells you what the employer wants. It almost never tells you what they will pay. Treating those as the same document is where most searches go wrong.

How to search when the signal is missing

The absence of disclosed ranges shifts the analytical work onto other signals. A few are more useful than most candidates apply them.

Work mode is one of them. Across the 1,776 postings in our corpus that state a work mode at all, 47% of postings that state a work mode are remote, 23% of postings that state a work mode are hybrid, and 30% of postings that state a work mode are on-site. That distribution matters for compensation analysis in ways that are not obvious. Remote roles draw from a national candidate pool, which tends to compress salary ranges toward the employer's preferred median rather than a regional premium. On-site roles in high-cost metros often carry implicit location adjustments that never appear in the posting but do surface in negotiation. A remote posting from an employer headquartered in a lower-cost region and a remote posting from a San Francisco-based biotech are not comparable starting points, even if the titles match.

Employer stage and funding structure carry more compensation signal than most postings reveal, but they are findable through other means. Pre-commercial biotechs at early funding stages typically have equity-weighted packages with modest base salaries; large commercial pharma often reverses that mix. Knowing where a prospective employer sits on that spectrum before a first call is basic preparation, and it is available without the posting telling you anything.

Role specificity is a useful filter. A posting dense with function-specific requirements — assay development, IND-enabling work, regulatory pathway detail, commercial launch experience — signals genuine need and typically a more defined internal budget than a broadly written posting fishing for candidates. Broadly written postings are more likely to be exploratory, which means the compensation conversation will be more variable and more dependent on how the employer assesses the specific candidate.

What this means for where you spend your energy

Zero disclosure across a corpus of 10,000 postings is a structural condition, not a correctable nuisance. It will not change because a candidate finds a better way to read job descriptions. The appropriate response is to change what you optimize for before you engage.

Roles surfaced through direct relationships — former colleagues, scientific collaborators, advisors to companies you track — are more likely to come with compensation context early, because the conversation is between people who already have baseline trust. The posting-first approach is a cold channel that hides the information you most need.

Knowing your own number with precision matters more in an opaque market than in a transparent one. If you do not have a clear, defensible sense of what a move requires in total compensation terms — base, bonus structure, equity, benefits differential — you will be negotiating against an employer who has that information about your situation and about their own budget. The asymmetry is already in their favor; imprecision on your side compounds it.

Selectivity is not inefficiency in this environment. A targeted search that produces fewer, better-qualified conversations is almost always more productive than broad application volume when compensation alignment cannot be pre-screened from postings. Volume feels like progress; fit is what produces outcomes.

Our corpus will update as the market moves. If disclosure rates change — and there are legislative pressures in several states that could eventually affect how employers write postings — we will report it as it happens. For now, the data says what it says: the market is not going to tell you what it will pay. Knowing that clearly is the beginning of a more disciplined search.